Omnix Medical Raises $25 Million in Series C Funding Round, Co-Led by Harel Insurance & Finance and the EIC Fund

— A partnership of current and new investors aims to speed up the development of Omnix’s innovative, pioneering antimicrobial pipeline

— The financing underscores the pressing worldwide demand for new antimicrobials capable of overcoming resistance

JERUSALEM, Israel, October 15, 2025 — Omnix Medical, a biopharmaceutical firm dedicated to creating advanced anti-infectives for severe infections, revealed today it has secured $25 million in Series C funding. This round was co-led by Harel Insurance & Finance and the EIC Fund. Current shareholders, including Entree Capital, Tal Ventures, Xenia Ventures, and Oriella Limited, reaffirmed their belief in Omnix’s strategy by participating, joined by new external investors such as Prevail Partners and OurCrowd.

This capital infusion will allow Omnix to finalize Phase II proof-of-concept trials for its primary compound, OMN6. These studies will concentrate on combating critical infections stemming from Gram-negative bacteria, notably Acinetobacter baumannii, including variants resistant to final-resort treatments like carbapenems and colistin. Additionally, the funds will facilitate regulatory processes, expand manufacturing capacity, and propel the development of Omnix’s wider array of engineered antimicrobial peptides. Following this latest investment round, Omnix has accumulated $43 million in total funding since its establishment in 2015.

Tomer Goldberg, Vice President, Managing Director of Harel Technology Investments at Harel Insurance & Finance, stated: “The increase in antibiotic-resistant infections represents not only a medical emergency but a societal one. Harel is committed to fostering innovation and biotech, and we consider companies like Omnix vital for guaranteeing the creation of potent treatments that safeguard lives and enhance long-term health.”

“Thanks to the joint leadership of Harel Insurance & Finance and the EIC Fund, coupled with the steadfast backing from our current shareholders, we now possess the necessary capital to finalize Phase II proof-of-concept studies for OMN6, reinforce our regulatory and manufacturing capacities, and progress our full pipeline,” commented Dr. Moshik Cohen-Kutner, Chief Executive Officer of Omnix Medical. “We are pleased by the support from new investors and the renewed confidence from our enduring shareholders. Collectively, this demonstrates belief in Omnix’s objective to provide truly groundbreaking anti-infective remedies.”

OMN6 stands as a pioneering antimicrobial peptide (AMP) featuring a unique mechanism of action (MoA) centered on disrupting bacterial cell membranes. Consequently, it acts rapidly, is bactericidal, and remains effective irrespective of the bacterial genotype or resistance phenotype. To date, OMN6 has demonstrated outstanding preclinical and clinical outcomes concerning its efficacy, potency, and safety, alongside impressive stability while retaining bioactivity. The U.S. FDA has awarded the compound Fast-Track and QIDP (Qualified Infectious Disease Product) status.

“OMN6’s distinct affinity for bacterial membranes, its swift pore-forming activity, and its engineered endurance represent fundamentally novel strategies for combating resistant pathogens,” stated Dr. Niv Bachnoff, Chief Scientific Officer. “These attributes not only facilitate quick and potent treatment but also markedly reduce the chance of resistance evolving. Bolstered by this funding, we are prepared to showcase OMN6’s capacity to revolutionize the management of multidrug-resistant infections.”

###

About Omnix Medical

Omnix Medical was established in 2015 within the VLX Ventures incubator with the mission to address the worldwide problem of drug-resistant bacterial infections. Since its inception, the company has received backing from the Israeli Innovation Authority, secured a highly competitive EIC Accelerator / Horizon 2020 grant from the European Union, and obtained research funding from the U.S. National Institutes of Health (NIH) to progress its primary initiative, OMN6.

Omnix’s proprietary technology utilizes engineered antimicrobial peptides crafted for precise targeting of bacterial membranes. OMN6 selectively attaches to the distinct lipid makeup of bacterial membranes, quickly forming pores that destabilize and obliterate them, resulting in rapid bacterial demise. Its swift mode of action, enhanced stability, and capacity to evade enzymatic breakdown allow for shorter treatment periods and reduce the potential for resistance development.

About Harel Insurance & Finance

Harel Insurance & Finance Group stands as a prominent financial institution in Israel, holding significant market shares in insurance, healthcare, and investment management.

About the EIC Fund
The European Innovation Council (EIC) Fund operates as a venture arm of the European Commission within the Horizon Europe program. It targets investments in influential, deep-tech enterprises throughout Europe, supplying enduring capital and strategic assistance to facilitate the growth of groundbreaking innovations in healthcare, energy, and digital sectors.

###

Corporate Contacts
Moshik Cohen-Kutner, CEO
+972-50-8698218

Niv Bachnoff, CSO
+972-54-238-6023
contact@omnixmedical.com

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68

Related Links
http://www.omnixmedical.com/
LinkedIn http://linkedin.com/company/omnix-medical